Table 2.
Correlation of RAD21 expression with clinicopathologic features (n = 94)
| RAD21 negative | RAD21 positive | P value | |
|---|---|---|---|
| Age | |||
| ≤ 50 years | 40 (70%) | 24 (65%) | 0.589 |
| > 50 years | 17 (30%) | 13 (35%) | |
| Tumor size | |||
| < 20 mm | 29 (55%) | 20 (59%) | 0.706 |
| > 20 mm | 24 (45%) | 14 (41%) | |
| Nodal status | |||
| Negative | 42 (74%) | 28 (76%) | 0.829 |
| Positive | 15 (26%) | 9 (24%) | |
| Grade | |||
| I | 2 (5%) | 1 (3%) | 0.128 |
| II | 7 (16%) | 13 (36%) | |
| III | 34 (79%) | 22 (61%) | |
| ERα | |||
| Negative | 22 (44%) | 17 (49%) | 0.677 |
| Positive | 28 (56%) | 18 (51%) | |
| HER2 status | |||
| Negative | 46 (96%) | 30 (91%) | 0.366 |
| Positive | 2 (4%) | 3 (9%) | |
| Relapse | |||
| Negative | 44 (79%) | 18 (51%) | 0.007 |
| Positive | 12 (21%) | 17 (49%) | |
| BCSS | |||
| Negative | 45 (80%) | 19 (54%) | 0.006 |
| Positive | 11 (20%) | 16 (46%) | |
BCSS, Breast cancer-specific survival.